Skip to main content

Table 2 Proportion of subjects administered non-glucocorticoid treatment regimens during first hospitalization (n = 180)

From: Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder

Treatment

n, (%)

Plasma exchange (PLEX)a

56 (31.1)

Rituximabb

52 (28.9)

Intravenous immunoglobulin (IVIg)c

33 (18.3)

Mycophenolate mofetil

23 (12.8)

Azathioprine

15 (8.3)

Cyclophosphamide

10 (5.6

Methotrexate

1 (0.6)

  1. Legend. Subjects were able to contribute to more than one treatment regimen therefore total does not equal 100%
  2. aPLEX + rituximab (n = 20)
  3. bRituximab only, without any of the above listed non-glucocorticoid agent (n = 23)
  4. cIVIg + rituximab (n = 8)
Back to article page

Multiple Sclerosis and Demyelinating Disorders

ISSN: 2056-6115

Contact us